| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/26/2007 | US20070172421 Substituted pyrrolidine-2-ones |
| 07/26/2007 | US20070172420 Ligands |
| 07/26/2007 | DE202006017020U1 Verwendung von Kalium-, Magnesium-, Calium- und Zink-Elektrolyten zur Behandlung des Elementemangel- und Austrocknungssyndroms Alzheimer und anderer Demenzen Use of potassium, magnesium, and zinc Calium- electrolyte for the treatment of Alzheimer syndrome Elementemangel- and dehydration and other dementias |
| 07/26/2007 | DE10303229B4 Ambroxol und Inhibitoren des Angiotensin Converting-Enzyms (ACE) umfassende Arzneimittel Arzneimittel-Zubereitung und ihre Verwendung zur Behandlung von neurodegenerativen Erkrankungen Ambroxol and inhibitors of the angiotensin converting enzyme (ACE) pharmaceutical compositions comprising drug preparation and their use for the treatment of neurodegenerative diseases |
| 07/26/2007 | DE102006051941A1 Multifunctional active agent mixture, useful as auxiliary material in virus vaccine or vaccine to treat cancer, comprises fraction of specific peptide in polypetide chain and fraction with essential and non-essential amino acids |
| 07/26/2007 | CA2637458A1 Use of a combination of morphine and at least one opiate antagonist to treat opiate dependency and prevent non-oral opiate abuse among opiate addicts |
| 07/26/2007 | CA2637449A1 Cyclohexyl sulfonamide derivatives having h3 receptor activity |
| 07/26/2007 | CA2637411A1 Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof |
| 07/26/2007 | CA2637062A1 Neuronal nicotinic receptor ligands and their use |
| 07/26/2007 | CA2636692A1 Method for treating huntington's disease by inhibiting dephosphorylation of huntingtin at s421 |
| 07/26/2007 | CA2636634A1 Cannabinoid-containing plant extracts as neuroprotective agents |
| 07/26/2007 | CA2636189A1 Azaindoles useful as inhibitors of janus kinases |
| 07/26/2007 | CA2636112A1 Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives useful for the treatment of alzheimer's disease via gaba receptors |
| 07/26/2007 | CA2636007A1 Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors |
| 07/26/2007 | CA2633761A1 Treatment of substance abuse |
| 07/26/2007 | CA2633329A1 Pyridine derivatives as sodium channel modulators |
| 07/25/2007 | EP1811035A1 Aspartic proteinase 2 (ASP2) |
| 07/25/2007 | EP1811033A1 Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| 07/25/2007 | EP1811025A1 Mutated amyloid protein |
| 07/25/2007 | EP1811018A1 Brain disposition marrow progenitor |
| 07/25/2007 | EP1810979A1 STABILIZED HUMAN IgG4 ANTIBODIES |
| 07/25/2007 | EP1810715A2 Combination comprising an agent decreasing VEGF activity and an agent decreasing EGF activity |
| 07/25/2007 | EP1810714A1 Use of a combination of heroin and naloxon for drug substitution |
| 07/25/2007 | EP1810679A2 Controlled release oxycodone compositions |
| 07/25/2007 | EP1810678A1 Use of morphine and naloxone for drug substitution |
| 07/25/2007 | EP1810675A1 Method for treating Huntington's disease by inhibiting dephosphorylation of huntingtin at S421 |
| 07/25/2007 | EP1810673A1 Therapeutic agent for interstitial cystitis |
| 07/25/2007 | EP1810671A1 Agent for recovery from cerebral fatigue |
| 07/25/2007 | EP1810670A1 Combination of Polamidone and Naloxone for the treatment of drug addiction |
| 07/25/2007 | EP1809745A2 COMPOSITIONS AND METHODS FOR SHORT INTERFERING NUCLEIC ACID INHIBITION OF NAv1.8 |
| 07/25/2007 | EP1809662A2 Deamidated interferon-beta |
| 07/25/2007 | EP1809650A2 Polymorphs of sarsapogenin |
| 07/25/2007 | EP1809633A1 Constrained compounds as cgrp-receptor antagonists |
| 07/25/2007 | EP1809632A2 Pyrazolo[4,3-d]pyrimidine derivatives useful as pde-5 inhibitors |
| 07/25/2007 | EP1809620A1 Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| 07/25/2007 | EP1809608A1 Pyrimidine and quinoline potentiators of metabotropic glutamate receptors |
| 07/25/2007 | EP1809606A1 Compounds having activity at nk3 receptor and uses thereof in medicine |
| 07/25/2007 | EP1809605A1 Quinoline as allosteric enhancers of the gaba-b receptors |
| 07/25/2007 | EP1809598A1 Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 07/25/2007 | EP1809597A1 Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 07/25/2007 | EP1809312A1 Use of 11-oh-erythravine, erythravine, erytrartine, pharmaceutical compositions and processes for producing these substances |
| 07/25/2007 | EP1809298A2 Neuroprotective spirostenol pharmaceutical compositions |
| 07/25/2007 | EP1809297A1 Imidazo[1,5a]triazolo[1,5d]benzodiazepine derivatives for the treatment of cognitive disorders |
| 07/25/2007 | EP1809290A2 Pyrimidine derivatives as ion channel modulators and methods of use |
| 07/25/2007 | EP1809288A1 Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases |
| 07/25/2007 | EP1809286A2 Method for treatment of movement disorders |
| 07/25/2007 | EP1809278A2 Combinations of pkc activators and pkc inhibitors for for alzheimer's disease treatment and cognitive enhancement |
| 07/25/2007 | EP1809273A2 Use of 2-phenyl-1,2-ethanediol-(di)carbamates for treating epileptogenesis and epilepsy |
| 07/25/2007 | EP1809271A2 (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators |
| 07/25/2007 | EP1809240A2 Cardiac safe, rapid medication delivery |
| 07/25/2007 | EP1809104A2 Methods for regulating neurotransmitter systems by inducing counteradaptations |
| 07/25/2007 | EP1658272B1 Novel gamma-secretase inhibitors |
| 07/25/2007 | EP1499600B1 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors |
| 07/25/2007 | EP1446135B1 Standardized extracts of scutellaria lateriflora |
| 07/25/2007 | EP1397364B1 Novel pyrrole derivatives as pharmaceutical agents |
| 07/25/2007 | EP1282610B1 Benzoxazine and benzothiazine derivatives and the use thereof in medicaments |
| 07/25/2007 | EP1143933B1 Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules |
| 07/25/2007 | EP1071419B1 Cannabinoids as antioxidants and neuroprotectants |
| 07/25/2007 | EP1056462B1 Use of rhamnolipids as cosmetics |
| 07/25/2007 | CN1328286C Aglyco products and method of use |
| 07/25/2007 | CN1328280C Tetrandrine and tetrandrine compound, synthesis and uses thereof |
| 07/25/2007 | CN1328247C N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists |
| 07/25/2007 | CN1327898C Anti-inflammatory fatty alcohols and fatty acid esters useful as antigen carriers |
| 07/25/2007 | CN1327878C Prepared Chinese medicine for treating insomnia and preparaton method |
| 07/25/2007 | CN1327859C Schisandra fruit extractive, its preparation process and purposes |
| 07/25/2007 | CN1327855C Effect of persimmon in drug addiction stopping medicine |
| 07/25/2007 | CN1327854C Quality control method of agavaceae extract medicinal formulation |
| 07/25/2007 | CN1327843C Use of flumazenil to produce medicament for treatment of cocaine dependency |
| 07/25/2007 | CN1327794C Table wine nutrition oral administration liquor for dispelling the effect of alcohol |
| 07/25/2007 | CN1327788C Health-care food |
| 07/25/2007 | CN101006097A Vla－4拮抗剂 Vla-4 antagonists |
| 07/25/2007 | CN101006072A Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| 07/25/2007 | CN101006047A TRPV1 agonists, formulations containing them and uses thereof |
| 07/25/2007 | CN101005845A Muscarinic antagonists with PARP and SIR modulatng activity as agents for inflammatory diseases |
| 07/25/2007 | CN101005842A Modulators of muscarinic receptors |
| 07/25/2007 | CN101005831A Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
| 07/25/2007 | CN101003829A Polypeptide of seed of spine date, preparation method, and application |
| 07/25/2007 | CN101003800A Cloning using donor nuclei from non-serum starved, differentiated cells |
| 07/25/2007 | CN101003573A Human antibodies that bind human tnfalpha |
| 07/25/2007 | CN101003567A Undecapeptide and application |
| 07/25/2007 | CN101003538A [1,4]diazocino[7,8,1-hi]indole derivatives as antipsychotic and antiobesity agents |
| 07/25/2007 | CN101003526A Stilbene derivatives and their use for binding and imaging amyloid plaques |
| 07/25/2007 | CN101003521A A compound valeryl biphenyl of valine |
| 07/25/2007 | CN101003520A A compound butyryl biphenyl of valine |
| 07/25/2007 | CN101003509A New pharmic acceptable salt of pyritinol, and preparation method |
| 07/25/2007 | CN101003500A Sodium sulfonate substitution compound in diphenyl heptane class, and preparation method, and application |
| 07/25/2007 | CN101003481A Preparing compound of phenols difluoro heptane category, and oxidation resistant applcation |
| 07/25/2007 | CN101002930A Medicine composition containing aniracetam and brain protein hydrolyte |
| 07/25/2007 | CN101002891A Oral traditional Chinese medicine for treating trifacial neuralgia |
| 07/25/2007 | CN101002890A Oral traditional Chinese medicine for treating liver-fire flaming trifacial neuralgia |
| 07/25/2007 | CN101002881A Oral traditional Chinese medicine for treating hemiplegia type hemidrosis |
| 07/25/2007 | CN101002879A Application of timosaponin for treating anxiety disorders |
| 07/25/2007 | CN101002878A Medicine for treating dementia |
| 07/25/2007 | CN101002865A Oral traditional Chinese medicine for treating rheumatismal trifacial neuralgia |
| 07/25/2007 | CN101002853A Oral medicine for treating cephalagra type hemidrosis |
| 07/25/2007 | CN101002844A Instant granulated medicine for sobering use and its preparing method |
| 07/25/2007 | CN101002841A Effective components of rose, its preparing method and use |
| 07/25/2007 | CN101002839A Use of wild jujube kernel alcohol extractive for treating anxiety disorders |
| 07/25/2007 | CN101002836A Use of the extractive of radix cynanchi bungei total glucoside |
| 07/25/2007 | CN101002810A Dripping pills of schefflera arboricola, and its preparing method |